The FDA has cleared C2N Diagnostics’ PrecivityAD2 blood test for marketing, giving physicians a less invasive way to identify amyloid plaques associated with Alzheimer’s disease in certain patients.
C2N Diagnostics developed and validated the test using underlying technology invented at Washington University School of Medicine in St. Louis, according to an Aug. 21 news release. PrecivityAD2 relies on high-resolution mass spectrometry to measure amyloid and tau biomarkers tied to amyloid pathology.
In previous studies, the test detected amyloid pathology with more than 90% accuracy, matching the performance of spinal taps and brain scans, even in patients with mild cognitive symptoms.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
